PSS14 COST-UTILITY ANALYSIS OF RANIBIZUMAB (LUCENTIS®) IN WET-AMD BASED ON REAL-LIFE DATA COLLECTED IN THE HELIOS STUDY AFTER RANIBIZUMAB REIMBURSEMENT IN BELGIUM

Saved in:
Bibliographic Details
Published inValue in health Vol. 14; no. 3; p. A55
Main Authors Moeremans, K, Gerlier, L, Drieskens, S, Annemans, L, Brié, H, Deruyck, M, Faes, P, Vancayzeele, S
Format Journal Article
LanguageEnglish
Published Elsevier Inc 2011
Subjects
Internal Medicine
Online AccessGet full text

Cover

More Information
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2011.02.316